Cargando…
S180. THE SELECTIVE GPR139 AGONIST TAK-041 REVERSES ANHEDONIA AND SOCIAL INTERACTION DEFICITS IN RODENT MODELS RELATED TO NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
BACKGROUND: Negative symptoms in schizophrenia (SCZ) are poorly treated and interfere with the function of patients. Studies focusing on structural and functional imaging and non-invasive electrophysiology implicate perturbations of the frontocortico-temporal circuits and disruption of cortico-stria...
Autores principales: | Schiffer, Hans, Atienza, Josephine, Reichard, Holly, Mulligan, Victoria, Cilia, Jackie, Monenschein, Holger, Collia, Deanna, Ray, Jim, Kilpatrick, Gavin, Brice, Nicola, Carlton, Mark, Hitchcock, Steve, Corbett, Ged, Hodgson, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234360/ http://dx.doi.org/10.1093/schbul/sbaa031.246 |
Ejemplares similares
-
S39. GPR139 AN OPHAN GPCR AFFECTING NEGATIVE DOMAINS OF SCHIZOPHRENIA
por: Atienza, Joy, et al.
Publicado: (2018) -
Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [(11)C]PHNO PET
por: Rabiner, Eugenii A., et al.
Publicado: (2021) -
Pan-Cancer Analysis and Drug Formulation for GPR139 and GPR142
por: Kaushik, Aman Chandra, et al.
Publicado: (2021) -
A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK‐041 in healthy participants and patients with stable schizophrenia
por: Yin, Wei, et al.
Publicado: (2022) -
Habenula GPR139 is associated with fear learning in the zebrafish
por: Roy, Nisa, et al.
Publicado: (2021)